This Article Full Text Full Text (PDF) All Versions of this Article: 2006-0227TRv1 36/1/8    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mattes, J. Articles by Foster, P. S. Search for Related Content PubMed PubMed Citation Articles by Mattes, J. Articles by Foster, P. S.

Regulation of MicroRNA by Antagomirs

A New Class of Pharmacological Antagonists for the Specific Regulation of Gene Function?

School of Biomedical Sciences, Faculty of Health and Hunter Medical Research Institute, University of Newcastle; John Hunter Children's Hospital, Newcastle, New South Wales; and John Curtin School for Medical Research, Australian National University, Canberra, Australia

Correspondence and requests for reprints should be addressed to Joerg Mattes and Paul Foster, School of Biomedical Sciences, Faculty of Health and Hunter Medical Research Institute, University of Newcastle, NSW 2300, Australia. E-mail: Joerg.mattes{at}newcastle.edu.au and Paul.foster{at}newcastle.edu.au

The discovery of small "noncoding" or "nonmessenger" RNA molecules that are repressors of translation (microRNAs) has provided the opportunity to specifically suppress a gene or clusters of genes. Moreover, the recent employment of synthetic analogs of these small RNA molecules termed "antagomirs" has shown that microRNAs of interest can be specifically targeted. Understanding the role of microRNAs in fundamental processes associated with complex diseases such as asthma, chronic obstructive pulmonary disease, cancer, chronic infections, and immune disorders may aid in disease diagnosis and prognosis and potentially identify new therapeutic targets.

CLINICAL RELEVANCE Understanding the miRNA signature in susceptible individuals may facilitate the partitioning of patients into distinct subpopulations for targeted therapy, aid in disease diagnosis and prognosis, and potentially identify new therapeutic targets.

 

This article has been cited by other articles:

				J. Mattes, A. Collison, M. Plank, S. Phipps, and P. S. Foster Antagonism of microRNA-126 suppresses the effector function of TH2 cells and the development of allergic airways disease PNAS, November 3, 2009; 106(44): 18704 - 18709. [Abstract] [Full Text] [PDF]

				R. K. Kumar, M. P. Hitchins, and P. S. Foster Epigenetic changes in childhood asthma Dis. Model. Mech., November 1, 2009; 2(11-12): 549 - 553. [Abstract] [Full Text] [PDF]

				Y. Chiba, M. Tanabe, K. Goto, H. Sakai, and M. Misawa Down-Regulation of miR-133a Contributes to Up-Regulation of RhoA in Bronchial Smooth Muscle Cells Am. J. Respir. Crit. Care Med., October 15, 2009; 180(8): 713 - 719. [Abstract] [Full Text] [PDF]

				A. J. Schetter, S. Y. Leung, J. J. Sohn, K. A. Zanetti, E. D. Bowman, N. Yanaihara, S. T. Yuen, T. L. Chan, D. L. W. Kwong, G. K. H. Au, et al. MicroRNA Expression Profiles Associated With Prognosis and Therapeutic Outcome in Colon Adenocarcinoma JAMA, January 30, 2008; 299(4): 425 - 436. [Abstract] [Full Text] [PDF]